Field Trip Health Ltd.’s $95 Million Bought Deal Financing

BLG represented the underwriters of the offering.

On March 17, 2021, Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (Field Trip), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has closed the bought deal short form prospectus offering previously announced on February 25 and 26, 2021, including the full exercise of the underwriters’ over-allotment option (the Offering). In connection with the Offering, Field Trip issued 14,661,499 common shares, (Common Shares) at a price of C$6.50 per Common Share, for aggregate gross proceeds of $95 million.

The lead investor in the Offering was Soleus Capital with additional participation by Avidity Partners, Sphera Funds, Pura Vida Investments, Jennison Associates and other healthcare specialized institutional investors. 

The Offering was conducted by Bloom Burton Securities Inc., as lead underwriter and sole bookrunner with Stifel GMP and Canaccord Genuity Corp. forming a syndicate of underwriters.

The BLG team comprised of Andrew Powers (Picture), Jason Saltzman, Ben Keen and Adam Ragusa.

 

 

Involved fees earner: Ben Keen – Borden Ladner Gervais; Andrew Powers – Borden Ladner Gervais; Adam Ragusa – Borden Ladner Gervais; Jason Saltzman – Borden Ladner Gervais;

Law Firms: Borden Ladner Gervais;

Clients: Bloom Burton & Co. Limited; Canaccord Genuity; Stifel GMP;

Author: Martina Bellini